Drug intelligence / Profile preview

dorsomorphin

Development stage
Preclinical
Lead developer
Massachusetts General Hospital
Modality
Small Molecules
Administration
Intraperitoneal, Intravenous
01

Overview

Dorsomorphin is a potent, reversible, and ATP-competitive small molecule inhibitor. It was initially identified as an inhibitor of AMP-activated protein kinase (AMPK), but it is also widely recognized for its potent inhibition of Bone Morphogenetic Protein (BMP) type I receptors, including ALK2 (ACVR1), ALK3 (BMPR1A), and ALK6 (BMPR1B). By blocking BMP signaling, dorsomorphin inhibits the phosphorylation of Smad1/5/8. It has been used extensively in research to study metabolic regulation, vascular biology, and embryonic development. While it has shown potential in preclinical models for treating conditions like anemia of chronic disease by suppressing hepcidin expression, it is primarily utilized as a pharmacological tool in vitro and in vivo rather than as a clinical therapeutic.

Other names
6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)AKT (RAC-alpha serine/threonine-protein kinase)ACVR1 (Activin receptor type I)BMPR1ABMPR1BMAPK3 (Mitogen-activated protein kinase 1)TAK1 (Transforming growth factor beta–activated kinase 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RK (Ribokinase)

Beyond the preview

Go deeper on dorsomorphin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dorsomorphin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call